CVE-2021-38374

Public Exploit

Description

OX App Suite through through 7.10.5 allows XSS via a crafted snippet that has an app loader reference within an app loader URL.

Category

5.4
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.16%
Third-Party Advisory packetstormsecurity.com Third-Party Advisory packetstormsecurity.com Third-Party Advisory seclists.org Third-Party Advisory seclists.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://www.open-xchange.com product
http://seclists.org/fulldisclosure/2021/Nov/43 mailing list third party advisory exploit
http://packetstormsecurity.com/files/165038/OX-App-Suite-7.10.5-Cross-Site-Scripting-Information-Disclosure.html third party advisory vdb entry exploit
http://seclists.org/fulldisclosure/2022/Jul/11 third party advisory mailing list
http://packetstormsecurity.com/files/167794/Open-Xchange-App-Suite-7.10.x-Cross-Site-Scripting-Command-Injection.html third party advisory vdb entry exploit

Frequently Asked Questions

What is the severity of CVE-2021-38374?
CVE-2021-38374 has been scored as a medium severity vulnerability.
How to fix CVE-2021-38374?
To fix CVE-2021-38374, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2021-38374 being actively exploited in the wild?
It is possible that CVE-2021-38374 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.